A peer-reviewed journal that offers evidence-based clinical information and continuing education for dentists.

Merck COVID-19 Vaccines Discarded Due to Low Efficacy


Two vaccines developed to prevent infection with the novel coronavirus have been abandoned due to poor performance in clinical trials. Manufactured by Durham, North Carolina-based Merck in partnership with the nonprofit organization IAVI, the two vaccines showed little ability to generate a strong immune response in initial clinical trials. Due to the disappointing results, the company has decided to forgo moving the vaccines to larger trials. Merck will now pivot to focus on its antiviral drug molnupiravir, which has shown preliminary success in treating COVID-19 illness. Click here to read more.

Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy